New Cancer Drugs · global
BioNTech’s mRNA therapy for head and neck cancer misses first primary endpoint; trial continues to assess overall survival
BNT113 combined with pembrolizumab did not significantly extend the time patients lived without disease progression. But under the prespecified trial design, the study could still yield a positive result if subsequent findings demonstrate that it prolongs life.
Can helping the immune system recognize cancer cells translate into a survival benefit for patients? BioNTech’s mRNA cancer immunotherapy BNT113 has encountered a setback in a head and neck cancer clinical trial. The company announced on October 13 that BNT113 combined with the immunotherapy drug pembrolizumab did not significantly improve progression-free survival compared with pembrolizumab alone, missing the first of two primary endpoints.
The Phase II/III trial, called AHEAD-MERIT, enrolled patients with unresectable, recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma whose tumors express PD-L1, with a combined positive score (CPS) of at least 1. The study compares two first-line treatment approaches to determine whether adding BNT113 can provide additional benefit over the existing immunotherapy.
Progression-free survival measures the time patients remain alive without their disease worsening; the other primary endpoint, overall survival, directly assesses how long patients live. The independent data monitoring committee recommended that the trial continue as planned to complete the overall survival analysis. Under the study’s prespecified statistical design, the trial can still yield a positive result if overall survival shows a statistically significant improvement, even though the first endpoint was not met. This provision was part of the original design, rather than a change in assessment criteria after the results became available.
BNT113 uses a fixed-antigen design, with mRNA encoding the HPV16 E6 and E7 proteins, aiming to trigger an immune response against tumor cells carrying these viral antigens. The therapeutic rationale is to combine it with an immune checkpoint inhibitor to enhance antitumor activity. This also means that its applicability depends on the tumor’s viral and molecular characteristics; these results cannot be directly extrapolated to all head and neck cancers or other mRNA cancer therapies.
AHEAD-MERIT began with a nonrandomized safety run-in phase to establish the safety and tolerability of the combination at the selected dose, followed by a randomized comparative phase. Under the trial design, treatment lasts up to approximately 24 months. In addition to the two primary survival measures, the study assesses safety, tumor response rate and duration of response.
Currently available public data remain insufficient to determine the size of the efficacy difference between the two groups. CancerNetwork noted that BioNTech did not release specific progression-free survival data in this update, so the announcement does not yet provide the hazard ratio, median survival times or subgroup results. Failure to reach statistical significance means that this analysis did not establish the expected improvement; it does not mean that the two treatments have been proven to be exactly equivalent.
BioNTech said that, under the trial’s management procedures, the company still has no access to unblinded data from the ongoing study. The overall survival results will next address whether this combination can prolong life, while the full efficacy and safety data will help assess the actual treatment value of adding BNT113. Until those answers become available, the monitoring committee’s recommendation to continue the trial should be understood as a necessary step toward completing the assessment, rather than confirmation of efficacy.